Cordis Corporation Announces Clinical Studies And Events At TCT 2007
Data Presentations and Symposia Highlight CYPHER(R) Sirolimus-Eluting Coronary Stent, The Most-Studied Drug-Eluting Stent
WARREN, NJ (October 17, 2007) - Cordis Corporation will present clinical data and professional education opportunities at the annual Transcatheter Cardiovascular Therapeutics 2007 meeting (TCT 2007), which will take place in Washington, DC from October 20 to 25. Data from several studies will highlight the CYPHER(R) Sirolimus-eluting Coronary Stent, as well as other products from the company's peripheral vascular group.
"The studies that will be presented at this year's meeting will continue to add to the significant body of scientific evidence for the CYPHER(R) Stent and our diverse portfolio of current and future products, which range from a carotid artery stent system to a wound closure device," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Corporation. "The studies and presentations will further validate the clinical advantages of drug-eluting stents compared with bare metal stents, highlight economic data of stenting versus surgery, and feature the clinical benefits of the CYPHER(R) Stent versus the Taxus Stent."
The schedule of key Cordis-related events includes:
SATURDAY, OCTOBER 20
3:15 p.m. Eastern Time (ET)
Carotid Workshop - Pooled Analysis of Three Carotid Artery Stenting Trials
Barry T. Katzen, M.D. of the Baptist Cardiac and Vascular Institute in Miami, Florida will present a pooled analysis of three carotid artery stenting trials to assess 30-day major adverse events rates, comprising death, all stroke and/or heart attack (myocardial infarction), in high-risk patients based on anatomic versus physiological risk factors. The analysis was pooled from the pivotal SAPPHIRE randomized and registry stent cohorts and the CASES-PMS study, which involved the PRECISE(R) Stent and ANGIOGUARD(R) Emboli Capture Guidewire.
No previous analysis has been reported regarding whether patients undergoing carotid artery stenting with emboli protection, who are at high-risk for carotid endarterectomy, have a higher risk for major adverse events based on anatomic versus co-existing physiological risk factors prior to carotid stenting. Additional analysis assessing one-year outcomes of these subgroups will also be presented.
3:32 p.m. ET
Oral Presentation - ECLIPSE Trial
S. Chiu Wong, M.D. of New York-Presbyterian Hospital/Weill Cornell Medical Center will present perspectives on extravascular sealing devices and a first report of the ECLIPSE Trial, a multicenter, non-blinded, randomized study designed to measure the safety and efficacy of the EXOSEAL(TM) Vascular Closure Device versus manual compression to close vascular access sites in patients having undergone diagnostic or interventional procedures.
The EXOSEAL(TM) Vascular Closure Device features a synthetic bioabsorbable polymer and is being studied to determine whether it can enable expedited hemostasis (the cessation of bleeding), faster patient ambulation (ability to walk) and reduced bed-stay after a catheterization procedure. Nearly eight million patients undergo cardiac catheterization procedures annually.
SUNDAY, OCTOBER 21
12:51 p.m. ET
Oral Presentation - ACROSS and PRISON II Trials
Ballroom C, Level 3
Dr. Kandzari will present six-month data results of the ACROSS Registry and PRISON II randomized clinical trial designed to evaluate the CYPHER(R) Stent used in patients with chronic total occlusions.
MONDAY, OCTOBER 22
7:00 p.m. ET
Symposium - "New Evidence in DES Outcomes: The Road Travelled Since the World Congress of Cardiology 2006"
Grand Hyatt Constitution Ballroom
A panel of distinguished speakers that includes Christian M. Spaulding, M.D., PhD of Cochin Hospital in France; Stephan Windecker, M.D. of Swiss Cardiovascular Center Bern in Switzerland; Jeffrey W. Moses, M.D., of Columbia University Medical Center in New York; and Lowell F. Satler, M.D. of Washington Hospital Center will discuss the drug-eluting stent landscape and how to apply current evidence to clinical practice. Topics of discussion will include the impact of media headlines on clinical practice, the latest data set on percutaneous coronary interventions, applying the evidence of drug-eluting stents to clinical practice and the future of sirolimus-eluting stents.
TUESDAY, OCTOBER 23
9:09 a.m. ET
Oral Presentation - "Temporal Trends in Coronary Revascularization Procedures, Outcomes and Costs: Results From the U.S. Medicare Program"
Jason W. Ryan, M.D., M.P.H. of Beth Israel Deaconess Medical Center in Boston, Massachusetts will present a comparison of pre-drug-eluting stent implantation in 2001 to post-drug-eluting stent implantation in 2004; Dr. Ryan will provide an update on temporal trends, outcomes and costs from this time period associated with coronary revascularization procedures, including percutaneous interventions and bypass surgery, from the Medicare program in the United States.
WEDNESDAY, OCTOBER 24
1:45 p.m. ET
OralPresentation - ARTS II
Coronary Theatre, Lower Level
Bernard De Bruyne, M.D., Ph.D. of Cardiovascular Center, OLV Hospital, Aalst, Belgium will present two-year data results from the ARTS-II Trial, which compared the safety and efficacy of the CYPHER(R) Stent versus BMS and CABG. Dr. Bruyne will present data from the study assessing the impact of gender following multivessel drug-eluting stent implantation.
About the CYPHER(R)Stent
The CYPHER(R) Stent is the most studied drug-eluting stent in history and has been chosen by cardiologists worldwide to treat more than 3 million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.
The CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of a sirolimus-eluting stent, the CYPHER SELECT(TM) Sirolimus-eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease.
Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a trademark of Wyeth Pharmaceuticals.
------------------------------------------------------------------------- To update your subscription, change your e-mail address or delete yourself from this list, please click on: http://www.investor.jnj.com/distlist.cfm.
------------------------------------------------------------------------- Service provided by Shareholder.com.
Posted: October 2007